Article Text

Download PDFPDF

Authors’ response to: How should we best determine the need for in-flight oxygen in patients with pulmonary arterial hypertension
  1. Dinesh Shrikrishna1,2,
  2. Luke Howard3,
  3. Robina K Coker1,4,
  4. on behalf of the Air Travel Working Party of the British Thoracic Society Standards of Care Committee
  1. 1 National Heart and Lung Institute, Imperial College London, London, UK
  2. 2 Department of Respiratory Medicine, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, UK
  3. 3 National Pulmonary Hypertension Unit, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
  4. 4 National Heart and Lung Institute, Hammersmith Hospital, London, UK
  1. Correspondence to Dr Robina K Coker, Department of Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; robina.coker{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Burns et al 1 for their comments on the updated British Thoracic Society recommendations for managing passengers with respiratory disease planning air travel.2 In particular, a central aim of the recommendations was to promote research in this field, and we therefore commend their recent study investigating hypoxaemia in patients with pulmonary arterial hypertension (PAH) during simulated air travel.3 The method of assessment which best serves a clinician in judging which patients with PAH require in-flight oxygen remains a challenge due to a lack of evidence. Indeed, the current recommendation that those PAH patients in New York Heart Association (NYHA) functional class III or IV should receive in-flight oxygen has only a grade D evidence base. Importantly, NYHA functional class does provide a key measure of the impact of the disease on patients and is a strong predictor of survival in PAH.4 In this context, the successful completion of a hypoxic challenge test (HCT) alone does not always translate to an absence of symptoms in flight for these patients.3 The question of whether NYHA functional class III–IV or HCT better predicts the requirement for in-flight oxygen in PAH, clearly remains open to debate, and we hope this will only serve to encourage further high-quality research in this area to strengthen the evidence base for future air travel guidelines.


View Abstract


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles